Join our daily newsletter At The Bell to receive exclusive market insights
4DX Medical (ASX:4DX) has seen its price jump back to $2.20/sh, up +10%, as its next-gen lung imaging scan tech gets picked up by the University of Miami (UoM). It’s a vindication of the company’s U.S. expansion, which is now the main value catalyst for the stock, at least in the eyes of its shareholders and investors.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Helping matters is that UoM are also commencing clinical use of the scanner, called CT:VQ, which makes it the second academic medical centre (AMC) in the States to adopt the tech, alongside none other than Stanford. The adoptions come after a relatively recent FDA approval for the device in that jurisdiction.
The arrangement provides “three months of introductory pricing,” 4DX clarified on Wednesday, indicating “full financial terms” will be arrived upon after. In other words: no dollar signs in Wednesday’s announcement. But that CT:VQ has made its way into a second America university has been enough to do the trick when it comes to risk-on decisions to hit the buy button.
“The immediate transition from strong RSNA engagement to commercial operations demonstrates the significant momentum we are seeing from clinicians seeking a contrast-free, high-resolution alternative to nuclear medicine VQ scans,” 4DX CEO Andreas Fouras said.
“This commercial launch comes on the heels of incredibly strong clinician interest at RSNA. I had the chance to meet leading radiologists from all over the U.S. who were eager to connect with 4DMedical, dive into the technology, and explore how it can make a real difference for their practices and their patients.”
4DX last traded at $2.20/sh.
Join the discussion: See what HotCopper users are saying about 4DX Medical Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
